Cancer Meeting Update

Article

The Eleventh Lung Cancer Congress will be held July 8-11, 2010 in Rancho Palos Verdes, California

The purpose of the International Lung Cancer Congress is to provide major cooperative groups hailing from the United States, Europe, and Asia with updates on recent breakthroughs in lung cancer research.  As in past years, the eleventh congress will address the study of lung cancer from different angles: biological, pathological, staging, personalized therapy and the ongoing research of Cooperative Groups.  The conference will also cover current topics of interest, such as maintenance therapy and novel targeted agents.
  

Congress participants have the opportunity to meet internationally prominent opinion leaders and take part in debates and discussions on controversial topics. Additionally, the meeting will adopt an original approach by including panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer.
  

The recurring theme throughout the conference will be non–small-cell lung cancer (NSCLC).  However, the congress reserves the right to address other areas of interest such as therapy for small-cell lung cancer (SCLC) and mesothelioma.
  

At the conclusion of the Congress, the participants will leave with a furthered understanding of the areas addressed, including:
• Appropriate therapy for patients with lung cancer based on biomarker status and tumor characteristics.
• Approaches to improve treatment outcomes with first and second-line therapies in advanced lung cancer.
• New approaches to deliver radiation therapy in lung cancer.
• Personalized therapeutic approaches for patients with mesothelioma. 
• Clinical data on new targeted agents in development for lung cancer.
• Current research activity in lung cancer from national and regional Cooperative Groups.

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content